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Diagnosis of Cystic Fibrosis in Screened Populations 
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Richard B. Parad, MD, MPH5, Margaret Rosenfeld, MD, MPH6, Olaf Sommerburg, MD7, Frank J. Accurso, MD8, 
Jane C. Davies, MBChB, FRCPCH, MD9, Michael J. Rock, MD1, Don B. Sanders, MD, MS10, Michael Wilschanski, MBBS11, 
Isabelle Sermet-Gaudelus, MD, PhD12, Hannah Blau, MBBS13, Silvia Gartner, MD14, and Susanna A. McColley, MD15
Objective Cystic fibrosis (CF) can be difficult to diagnose, even when newborn screening (NBS) tests yield posi- 
tive results. This challenge is exacerbated by the multitude of NBS protocols, misunderstandings about screening 
vs diagnostic tests, and the lack of guidelines for presumptive diagnoses. There is also confusion regarding the 
designation of age at diagnosis. 
Study design To improve diagnosis and achieve standardization in definitions worldwide, the CF Foundation 
convened a committee of 32 experts with a mission to develop clear and actionable consensus guidelines on 
diagnosis of CF with an emphasis on screened populations, especially the newborn population. A comprehensive 
literature review was performed with emphasis on relevant articles published during the past decade. 
Results After reviewing the common screening protocols and outcome scenarios, 14 of 27 consensus statements 
were drafted that apply to screened populations. These were approved by 80% or more of the participants. 
Conclusions It is recommended that all diagnoses be established by demonstrating dysfunction of the CF 
transmembrane conductance regulator (CFTR) channel, initially with a sweat chloride test and, when needed, 
potentially with newer methods assessing membrane transport directly, such as intestinal current measurements. 
Even in babies with 2 CF-causing mutations detected via NBS, diagnosis must be confirmed by demonstrating 
CFTR dysfunction. The committee also recommends that the latest classifications identified in the Clinical and 
Functional Translation of CFTR project [http://www.cftr2.org/index.php] should be used to aid with CF diagnosis. 
Finally, to avoid delays in treatment, we provide guidelines for presumptive diagnoses and recommend how to 
determine the age of diagnosis. (J Pediatr 2017;181S:S33-44). 
ystic fibrosis (CF) is the most common life-threatening 
autosomal reces- sive disease in the US, occurring in 
approximately 1 in 4000 newborns.1-3 Since 1989, it has 
become well known that CF is an ion channel disorder 
caused by mutations in the gene for the CF transmembrane 
conductance regu- lator (CFTR).4 There are more than 2000 
mutations identified to date,5 approxi- mately 10%-15% of which 
have so far been confirmed to be CF-causing alleles.6 There has 
been a surprising degree of difficulty encountered worldwide in 
estab- lishing the diagnosis in a minority of cases and because of 
this, healthcare pro- viders continue to be faced with uncertain 
cases and challenging diagnostic dilemmas. Although the 
diagnosis of CF has traditionally relied on recognition of 
characteristic clinical signs and symptoms, the increased use of 
prenatal popu- lation screening for maternal CF carrier status, 
prenatal ultrasound screening (that 
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CF Cystic fibrosis 
CFFPR CF Foundation Patient Registry 
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CFTR CF transmembrane conductance regulator 
CRMS      CFTR-related metabolic syndrome 
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ICM Intestinal current measurement 
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NPD Nasal potential difference   
PAP Pancreatitis-associated protein 
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might reveal meconium ileus, meconium peritonitis, 
bowel ob- struction, or echogenic bowel), and 
newborn screening (NBS) has resulted in the 
routine diagnosis of asymptomatic or mini- mally 
symptomatic infants and a consequent 
opportunity to foster their normal growth and 
development. Since 2010 when nationwide CF 
NBS began in the US because of endorse- ments 
by the US Centers for Disease Control7 and the 
CF Foundation,8 the proportion of newly diagnosed 
patients iden- tified through screening has 
progressively increased. In fact, in the US, 
approximately 64% of new CF diagnoses now follow 
positive NBS. 
According to consensus guidelines developed by 
the CF Foun- dation in 2007 and published in The 
Journal in 2008,9 indi- viduals identified by NBS can 
be diagnosed with CF by a sweat chloride value ≥60 
mmol/L, or a level of 30-59 mmol/L if they have 2 
CF-causing mutations in the CFTR gene. Although 
the vast majority of screened infants can be 
unequivocally diag- nosed with CF by high levels of 
sweat chloride following a posi- tive newborn 
screen,9,10 the decision is not clear-cut in a 
significant number of individuals.11-13 Unclear 
diagnoses lead to treatment delays, persistent 
challenges,14 and stress and con- fusion for both 
families15,16 and clinicians.17 This group of infants, with 
varying levels of symptoms and a variety of CFTR 
mu- tations, has been the focus of discussions in 
the US and in Europe, with somewhat differing 
conclusions on both diag- nosis and 
management.18,19 In addition, there has been a 
lack of international harmony regarding 
terminology, leading to con- fusion reflected in a 
recent article, entitled “Comparing the American 
and European diagnostic guidelines for cystic fi- 
brosis: same disease, different language?”20 
Although treatment advances over the past 
several decades have raised the median predicted 
survival age from the midteens in the 1970s to 
more than 40 years of age today in the US21 and 
many countries in Europe,22,23 and more than 50 
years in Canada24 and in addition new CFTR 
modulator therapies offer great promise,25 
achieving optimal outcomes for all ages depends 
on timely and accurate diagnosis.26,27 
Continued improve- ment in predicted survival 
requires careful attention to diag- nostic 
recommendations. Despite efforts to reach and 
sustain a consensus on diagnostic criteria, 
however, it has become in- creasingly clear 
during the past few years that CF Founda- tion 
guidelines published in 2008 are not being used 
consistently and are considered obsolete by 
many clinicians.14 
During the process of developing the 2008 
guidelines, it was recognized that CF NBS 
introduced a new complexity and di- agnostic 
dilemma, namely infants with abnormal screening 
tests because of elevated immunoreactive 
trypsinogen (IRT) levels but inconclusive sweat tests 
and/or DNA results. Some infants with a high IRT, for 
example, can display an initial sweat chlo- ride level 
below the lowest accepted value for a potential CF 
diagnosis (30 mmol/L), even in the presence of 2 CF-
causing mutations.12,28 More common, however, are 
infants with high IRT levels and sweat chloride levels 
below CF diagnostic levels who have fewer than 2 CF-
causing mutations.12 This latter sce- nario has led to 
a new diagnostic term and management guide- 
lines, published in The Journal,19 in an article that 
created the term CFTR-related metabolic syndrome 
(CRMS). 
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In an effort to resolve the current diagnostic 
challenges fol- lowing a positive CF NBS result, 
participants in the 2015 Di- agnosis Consensus 
Conference included the following objectives in 
their mission: to develop revised guidelines for 
NBS-linked diagnosis, as well as for babies born 
after positive prenatal testing (ie, positive fetal 
diagnostic testing, including sweat test re- 
quirements and use of genetic data). Consensus 
recommen- dation statements that apply to 
the screened population, developed as a result 
of this conference29 are presented in Table I. 
 
 
The Many Potential Meanings of a Positive 
CF NBS Test 
 
A positive CF newborn screen is a result that 
demands prompt follow-up to identify infants 
with CF. However, CF NBS pro- grams vary 
considerably in design, and the type of NBS al- 
gorithm used to produce a positive screening 
result affects the positive predictive value, 
follow-up, and diagnostic processes. All CF NBS 
programs begin with detection of a high IRT 
level in a dried blood specimen from the 
newborn. In the US, this is routinely followed 
either by a second IRT measurement (IRT/IRT) or 
by use of a variety of CFTR mutation panels 
(usually 23-40 mutations30) (IRT/DNA). IRT/IRT is 
used fol- lowing approximately 10% of all US 
births, but its use is de- clining, because of lower 
sensitivity,31 delayed completion,32 and higher 
false-negative rate33 compared with IRT/DNA 
NBS al- gorithms. A variation of the IRT/DNA 
method, called IRT/ IRT/DNA,  requires  the  
demonstration  of   persistent 
hypertrypsinogenemia for 1-2 weeks before DNA 
is analyzed.34 The time to diagnosis may be 
longer than in IRT/DNA pro- grams, but a study 
suggests the IRT/IRT/DNA screen is more 
sensitive and detects fewer carriers.34 
Once a positive CF NBS result has been found, 
sweat chlo- ride testing must be performed to 
establish a CF diagnosis (Table I, statement 3). 
Some CF NBS programs in the US that use IRT/IRT 
have added sweat testing, combined selectively 
with DNA analysis, for follow-up to the 
biomarker screening. However, requiring sweat 
testing of all infants with positive IRT/IRT tests 
can be logistically problematic, such as when the 
infant does not live close to an accredited sweat 
test facility. Performing a sweat chloride test in 
infants receiving neonatal intensive care, who are 
more likely to have high IRT values because of 
nonspecific pancreatic stress,35 can also be chal- 
lenging, either because they are preterm or <2 
kg in weight (Table I, statement 2), are on 
supplemental oxygen, or cannot leave the intensive 
care unit for the test. In these cases, CFTR mutation 
analysis can play a role in the initial evaluation even 
in CF NBS programs that measure biomarkers 
alone. 
Most US CF NBS programs now include some 
form of DNA analysis in a second or third tier of 
screening.36 The type of analysis performed 
depends on state laws and demographics of the 
population being screened,37 but usually involves a 
panel of 23-40 of the most common CF-causing 
mutations. Some CF NBS programs subject the 
DNA to a more comprehensive genetic analysis.38-
40 Although a more detailed analysis can improve 
the detection of CF in nonwhite populations,41 it 
can 
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Table I. 2015 CF Foundation diagnosis consensus conference recommendations related to diagnosis of CF in the screened 
population* 
Statement 
numbers* Consensus statements 
2 Newborns with a positive CF newborn screen, to increase the likelihood of collecting an adequate sweat specimen, should have the test performed 
bilaterally and when the infant weighs >2 kg, and is at least 36 wk of corrected gestational age. 
3 Newborns greater than 36 wk gestation and >2 kg body weight with a positive CF newborn screen, or positive prenatal genetic test, should have sweat 
chloride testing performed as soon as possible after 10 d of age, ideally by the end of the neonatal period (4 wk of age). 
4 In infants with presumptive CF identified through NBS, CF treatment should not be delayed while efforts to establish a diagnosis of CF are initiated. 
6 In individuals presenting with a positive newborn screen, clinical features consistent with CF, or a positive family history, a diagnosis of CF can be made if 
the sweat chloride value is ≥60 mmol/L. 
7 Individuals who are screen-positive and meet sweat chloride criteria for CF diagnosis should undergo CFTR genetic testing if the CFTR genotype was not 
available through the screening process or is incomplete. 
8 In individuals with a positive newborn screen, a sweat chloride <30 mmol/L indicates that CF is unlikely. 
10 Individuals presenting with a positive newborn screen, symptoms of CF, or a positive family history, and sweat chloride values in the intermediate range 
(30-59 mmol/L) on two separate occasions may have CF. They should be considered for extended CFTR gene analysis and/or CFTR functional analysis. 
12 In individuals presenting with a positive newborn screen, symptoms of CF, or a positive family history, the identification of 2 CF-causing mutations (defined 
by CFTR2) is consistent with a diagnosis of CF. Sweat chloride testing is necessary, though, to confirm the diagnosis. 
13 The absence of detection of 2 CF-causing CFTR mutations does not exclude a diagnosis of CF. 
14 If further CF functional testing is needed (NPD and ICM), it should be performed in a validated reference center with trained staff certified by the CF 
Foundation TDN or ECFS Clinical Trial Network. 
15 In individuals with a positive newborn screen but variable or uncharacterized CFTR mutations (<2 CF-causing mutations), the diagnosis of CF can be made 
by demonstrating CFTR dysfunction (a sweat chloride ≥60 mmol/L or CF-typical NPD or ICM). 
18 The definition of CRMS/CFSPID is an infant with a positive NBS test for CF and either: 
• A sweat chloride <30 mmol/L and 2 CFTR mutations, at least 1 of which has unclear phenotypic consequences 
OR 
• An intermediate sweat chloride value (30-59 mmol/L) and 1 or 0 CF-causing mutations 
19 Children designated as CRMS/CFSPID should undergo at least 1 repeat sweat chloride test at CF centers with suitable expertise, such as an accredited CF 
center. 
20 Children designated as CRMS/CFSPID should have clinical evaluation performed by CF providers to identify the minority that may develop clinical 
symptoms. 
 
CTN, clinical trial network; ECFS, European CF Society; TDN, therapeutics development network. 
*Adapted from Farrell et al.29 
 
also result in the detection of many more infants 
with unclear diagnostic results.13 
An approach taken by some US CF NBS 
programs to improve sensitivity is the institution of a 
“safety net.” (The term “failsafe” is also used,36 
although it must be cautioned that false- negative 
screening tests will still occur.) Safety net design differs 
between programs. In CF NBS programs using DNA 
analysis as a second tier of screening, if the DNA 
suggests CF, the infant is referred for diagnostic 
confirmation by sweat test. However, even if the 
second-tier DNA screen does not detect a panel mu- 
tation, infants with very high IRT (VHIRT) values 
may still be referred for diagnostic sweat chloride 
testing. These CF NBS programs include algorithms 
such as IRT/DNA/VHIRT,42 IRT/IRT1↑/DNA,43 or 
IRT/DNA/IRT.44 In all cases, sensitiv- ity and 
specificity of algorithms using VHIRT must be evalu- 
ated, as has been done in New York.42 
The use of VHIRT as a safety net also has 
been used elsewhere, including France45 and the 
United Kingdom.46 In the United Kingdom, the 
national NBS program uses  a safety net for 
infants with a VHIRT value but no mutations 
identified on a limited mutation panel. The United 
Kingdom approach is to undertake a repeat IRT 
measurement on a sample obtained on day 21 of 
life. If the IRT value remains elevated at this stage, 
the NBS is reported as positive, and the infant 
referred for diagnostic assessment. This safety 
net approach has been useful for identifying 
infants with CF from a diverse ethnic population 
but at the expense of reducing positive predictive 
value. The adoption of various safety net 
algorithms is being considered by at least 9 Euro- 
SUPPLEMENT February 
2017 
Diagnosis of Cystic Fibrosis in Screened Populations S37 
 
 
pean nations (Olaf Sommerburg, personal 
communication, October 2015). 
Because of diverse political and 
demographic circum- stances, there are at least 
32 separate CF NBS programs in Europe, using a 
host of different screening algorithms.47-53 While 
still using IRT as the first tier of screening, some 
European pro- grams have incorporated a 
second biomarker, pancreatitis- associated 
protein (PAP), into their CF NBS algorithms. 
Although issues have surfaced regarding PAP cut-
off values,47,52,54 there are significant advantages 
of adding PAP analysis as a second tier of 
screening, including decreased recognition of 
carriers.55,56 However, using PAP analysis may also 
result in lower sensitivity. Methods to enhance 
sensitivity depend on the al- gorithm being 
used. While in France, Sarles et al52 decreased the 
PAP cut-off values recently to reach sufficient 
sensitivity, programs in Germany incorporated a 
failsafe strategy in which not only infants with 
high IRT and high PAP are referred for sweat 
testing, but also infants with low PAP values are 
re- ferred for sweat testing if they display 
ultrahigh IRT levels (IRT/PAP-failsafe).48 Pure 
biochemical IRT/PAP protocols nev- ertheless 
show a poor positive predictive value. More than 
two- thirds of all European CF screening 
programs use DNA, in accordance with the 
European CF Society recommendations,57 
Programs can still benefit from the use of PAP 
when com- bined with genetic analysis as a third 
tier as demonstrated by Vernooij-van Langen et 
al51 in 2012. Those protocols show not only 
sufficient sensitivity but also a positive predictive 
value comparable to that of IRT/DNA programs. 
Because of this ex- perience, IRT/PAP/DNA 
protocols will be implemented as a 
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national screening program from 2016 and 2017 
in Germany and in France, respectively. In a post 
hoc analysis, the effect of an ultrahigh-IRT safety 
net was demonstrated for the German 
IRT/PAP/DNA CF NBS program (Olaf 
Sommerburg, per- sonal communication, 
October 2015). In this NBS program, a high IRT 
leads to PAP analysis as the second-tier screen, and 
elevated PAP leads to the third-tier screen, that is, 
analysis for 31 CF-causing mutations. Data 
obtained from 372 906 neo- nates screened from 
2008 to 2015 in southwest Germany were used to 
compare the potential impact of an ultrahigh IRT 
safety net that could trigger either sweat testing 
or DNA analysis in the absence of an elevated PAP 
level. If ultrahigh IRT trig- gered sweat testing, 
approximately 345 infants would undergo this 
diagnostic procedure. If ultrahigh IRT led instead 
to re- quired DNA analysis, only 79 infants would 
subsequently undergo sweat testing. In either 
case, 71 infants with CF would be detected. 
The diversity of CF NBS algorithms leads inevitably 
to a spec- trum of risk for CF subsequent to a 
positive screen result. The likelihood of a “positive 
CF newborn screen” resulting in a di- agnosis of CF 
can vary hugely, from close to 100% (as may occur 
if 2 CF-causing mutations are identified) to around 
1% (as may occur in infants with positive NBS 
results because of VHIRT42). Some infants present 
for follow-up without any sup- porting genetic 
information, whereas others may have had ex- 
tensive genetic analysis performed. Regardless of 
the algorithm used, it must be emphasized that CF 
NBS is not a diagnostic test, and whether or not 
the baby has CF must be determined in follow-up 
care by diagnostic testing. As stated above, the 
essential component of this determination is the 
sweat test; the identification of a physiological 
abnormality not only sup- ports the positive NBS 
result but may also help the family accept the 
diagnosis.58 Clearly, the CF diagnosis is a serious 
one, and the sweat test provides an important 
safeguard to avoid mis- labeling babies because of 
identity errors, or laboratory errors in IRT or DNA 
analysis.59,60 Furthermore, the sweat test will be 
performed on siblings,61 and comparison data can 
be in- valuable. Even though there may appear to 
be less need of a sweat test in the presence of 
meconium ileus because meco- nium ileus 
provides obvious evidence of a physiological defect, 
a sweat test revealing elevated chloride should still 
be the cri- terion to confirm the diagnosis. There 
have been many in- stances where a neonatologist 
or surgeon did not properly inform the parents of 
an infant with meconium ileus about the high 
probability of CF, leading them to unrealistic 
expectations. 
Thus, the next step in the follow-up of a positive 
NBS or prenatal test that suggests CF must be 
determination of the sweat chloride 
concentration. However, its interpretation and any 
additional tests needed to further explore the 
possibility of the CF diagnosis depend on the NBS 
algorithm used. 
 
Confirming CF Diagnosis after Positive 
Newborn Screen without Detection of 
CF-Causing Mutations 
 
Some positive results from a CF newborn screen do 
not include a DNA screen (for example, those using 
an IRT/IRT screen); 
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in this case, a sweat chloride test is directed, and 
the nature of the follow-up is determined by the 
chloride levels found (Table I, statements 6, 8, 
10). If the sweat chloride level is 
≥60 mmol/L, the infant has CF and CFTR genetic 
testing should be done (Table I, statement 7). 
In most cases, if no CF-causing6 mutations are 
found in a CF NBS program that includes DNA 
analysis, the infant would be considered screen-
negative. A safety net (such as very high or 
ultrahigh IRT), however, could be triggered to 
direct a sweat chloride test, with follow-up again 
determined by the chlo- ride levels found (Table 
I, statements 6, 8, 10). 
 
 
Confirming CF Diagnosis after Positive 
Newborn IRT/DNA Screen with Detection 
of 2 CF-Causing Mutations 
 
Even with the identification of 2 CF-causing 
mutations (Table I, statement 11), the next step 
in a diagnostic work- up must be sweat chloride 
analysis (Table I, statement 12). Regardless of 
increased understanding of CFTR genetics, 
experts continue to emphasize the need for 
proof of CFTR dysfunction to complete the CF 
diagnosis.14,62 Some CF NBS programs 
demonstrate very high adherence; in France, for 
example, sweat test results are reported for up 
to 95.4% of infants with 2 CF-causing mutations 
(excluding those with meconium ileus),63 but the 
same is not true for all CF NBS programs.58 A 
review of diagnostic practices in the European 
Union showed that only 13 of 26 CF NBS 
programs reported routinely including sweat 
testing for infants with 2 CF- causing 
mutations.58 Four programs never conducted 
sweat testing in these infants, whereas it was 
sometimes conducted in 6 other programs. 
Analysis of data in the US CF Founda- tion 
Patient Registry (CFFPR) suggests a similar lack 
of adherence to this guideline: nearly 24% of US 
patients with 2 CF-causing mutations do not 
have associated sweat chlo- ride results.11 
Although the policy of a CF NBS program may be 
to recommend sweat chloride confirmation, the 
responsi- bility for performing the test resides 
with the primary care provider and the CF 
clinician assuming care. If the decision is made 
by the diagnostician to assign a diagnosis of 
CF without sweat chloride testing, the CF NBS 
program is left without these data, as are the CF 
patient registries. 
Improving adherence may require a better 
understanding of the potential challenges in 
sweat testing young infants and improved 
performance of sweat test procedures: (1) the 
sweat test itself remains challenging because of 
higher rates of insufficient sweat (quantity not 
sufficient) in neonates; 
(2) the diagnosis of CF already seems confirmed 
to some parents when they arrive with the baby 
at a CF center; (3) the presence of intermediate 
sweat chloride levels in babies with 2 CF-causing 
mutations can cause confusion in the family and 
primary care providers; (4) it may be difficult to 
order a sweat test if it has been postponed and a 
CF diagno- sis has been presumptively made and 
recorded in a medical chart; (5) sweat test results 
do not impact follow-up modali- ties in these 
infants; (6) sweat test results, unlike genetic 
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analysis, do not provide utility for personalized 
medicine; 
(7) because of the high costs of analytic devices, 
sweat chloride testing often is not performed 
in countries that have limited resources or 
consider CF rare; and (8) reimburse- ment for sweat 
testing may be problematic; in many areas of the 
world, including some of the US, the sweat test 
is not part of NBS funding, and health insurance 
companies may not pay for the test, and certainly 
not for a repeat sweat test, if they believe it is 
unnecessary. 
Despite these issues, it is clear that sweat tests 
can be performed successfully in most infants 
during the first month of life.44,64 Rock and 
Farrell64  reported that patients diag- nosed in 
Wisconsin following positive CF NBS from 2004 to 
2014 had sweat testing performed at a mean age 
of 21 days (SD of 16 days) and a median age of 16 
days. There were 2 infants whose sweat testing 
was delayed, which skewed the data distribution 
(an infant who had meconium ileus with surgery 
and  prolonged  hospitalization,  with  sweat  test 
at 55 days  of  age,  and  an  infant  born  
prematurely  at 34 weeks’ gestation, who was 
identified as a homozygous c.1521_1523delCTT 
[legacy: F508del] patient with birth weight of 2126 g 
and whose sweat test was delayed until 100 days of 
age to ensure a sufficient quantity of sweat). This 
study used the Gibson-Cooke method. Other 
data show similar, if not better results regarding 
adequate sweat quantity with the Macroduct 
collector (Wescor Inc, Logan, Utah).65 
It is important to explore ways to improve 
adherence. Re- quiring sweat test results for entry 
into the European and US CF Foundation data 
registries might emphasize the need for the 
information for diagnosis. Thus, beginning in 
2017, the CF Foundation will require that a sweat 
chloride value be entered for enrollment of a 
newly diagnosed patients in the CF registry. 
In addition to the sweat test, CFTR gene analysis 
on DNA obtained directly from the infant should 
ideally be per- formed as part of the diagnostic 
evaluation, even if a genotype was reported as part 
of the newborn screen (Table I, state- ment 2). This 
recommendation is new but is appropriate in the 
expanding era of CFTR modulator therapy in which 
the genotype must be known unequivocally. 
Although this group of infants has 2 reported CF-
causing mutations, some CFTR mutations (such as 
c.3717 + 12191 C→T [legacy: 3849 + 10kB C→T] and 
c.3454G>C [legacy: D1152H]) are known  to result 
in an increased probability of a sweat chloride 
level well below 60 mmol/L, even into the 
“normal” range, in individuals with CF.66-70 In the 
case of certain other muta- tions, a more in-depth 
genetic analysis may be useful. For example, if the 
c.350G>A mutation (legacy: R117H) is iden- tified, 
exploration of the polyT status and possibly TG 
repeats is essential because of their effects on both 
function and penetrance.71-73 Such in-depth genetic 
analysis is not always done as part of the diagnostic 
evaluation following CF NBS. However, because the 
polyT tract is highly significant in individuals with 
R117H, it should be added to the diagnostic 
evaluation to better identify, early on,  infants with  CF  
vs those who should be categorized as CRMS/CF 
screen posi- tive, inconclusive diagnosis (CFSPID), with 
a risk of converting 
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to a CF diagnosis74 (Appendix, case study 1; 
available at www.jpeds.com). There are also 
uncommon instances of 2 CF-causing 
mutations occurring in cis60,75; in this scenario, 
the sweat test would be normal and additional 
genetic analy- sis including parental testing 
could explain the result and prevent 
medicalization of this healthy infant. 
 
 
Confirming CF Diagnosis after Positive 
Newborn Screen with Detection of 
1 CF-Causing Mutation 
 
Not all infants with CF will have 2 CF-causing 
mutations de- tected (Table I, statement 13). 
Because of the lack of clarity on the disease 
liability of various CFTR mutations, the sweat test 
is an especially crucial part of the diagnostic 
algorithm for this group of infants (Table I, 
statements 10, 15), but inter- pretations can be 
difficult. The mutation effects are not always clear-
cut because of the presence of modifier genes, 
or envi- ronmental or epigenetic influences: the 
same mutations may be associated with CF in 
some patients, but with CRMS/ CFSPID in 
others.18 
In general, in this group of infants, a sweat 
chloride level 
≥60 mmol/L is clearly indicative of CF (Table I, 
statement 
15) and a sweat chloride level <30 mmol/L 
indicates CF is unlikely (Table I, statement 8). A 
sweat chloride level of 30-59 mmol/L, however, 
should lead to a second sweat test (Table I, 
statement 19). Often, this second sweat test will 
produce resolution of the intermediate 
screening test result, with a decrease to <30 
mmol/L resulting in discharge from the 
program as healthy, or an increase to ≥60 
mmol/L as diagnostic of CF. However, in some 
instances the sweat chloride levels remain 
intermediate and inconclusive. In this scenario 
(1 detected CF-causing mutation), extended 
genotyping, clinical evaluation by a CF specialist 
by 2 months of age, and another sweat chloride 
test repeated by 6 months of age are 
recommended to seek resolution.18,19 
Asymptom- atic infants who continue to display 
intermediate sweat chloride levels (30-59 
mmol/L) and whose genetic analysis does not 
provide clarity (<2 CF-causing mutations) 
should be categorized as CRMS/CFSPID and 
followed at a CF care center (Table I, statements 
18 and 20). (More details on frequency of 
CRMS/CFSPID, appropriate diagnostic evalua- 
tion, and outcomes  can  be  found  in  the  report  
by  Ren et al.74) Some CF NBS programs may 
use nasal potential difference (NPD) or other tests 
to clarify CFTR physiological dysfunction, 
particularly if insufficient sweat can be col- 
lected for analysis. 
Although it is appropriate from the perspective of 
both phy- sician and patient to label newborns 
who screen positive with intermediate sweat 
chloride values and <2 CF-causing muta- tions as 
CRMS/CFSPID, when patients display a clear history 
of CF-like lung disease plus intermediate sweat 
chloride and abnormal NPD/intestinal current 
measurement (ICM), they need CF management 
and must be diagnosed with CF. 
Infants whose newborn screen has identified 2 
CFTR mu- tations with ≤1 known to be CF-
causing and who display 
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normal sweat chloride levels should also be 
categorized as CRMS/CFSPID and followed (Table 
I, statement 18). 
Infants who are screen positive with 1 CF-
causing muta- tion but who produce insufficient 
sweat for analysis should be retested as described 
in Farrell et al29 (Appendix, case study 2). 
 
 
Additional Tests 
 
A small percentage of infants who are eventually 
diagnosed with CF do not meet definitive CF 
diagnostic criteria at the time of their fi evaluation 
following a positive CF NBS result. Typically, in this 
group, sweat chloride levels do not provide the 
information needed to properly identify CF. 
Extended geno- type (or any genotype) results 
may not be available initially, and even with the 
substantial progress of the past decade, will not be 
able to resolve all cases because of extremely rare 
alleles with insuffi clinical data or partially penetrant 
alleles with variable clinical consequences that 
cannot be predicted. Thus, we must turn to other 
possible biomarkers to provide an un- 
derstanding of the level of CF risk for these 
families as well as appropriate care for the 
patients. Embracing a wide array of biomarkers 
may help clinicians face the challenge of defin- ing 
the risk of CF for children with inconclusive genetic 
data. Gathering information about these 
biomarkers in early child- hood would help 
evaluate the penetrance of CFTR variants and 
describe the full spectrum of disorders associated 
with CFTR mutations, extending our knowledge 
about how CFTR vari- ants (and other genes) 
contribute to disease beyond our current 
understanding of CF. 
 
Fecal Elastase (FE) 
Demonstration of low FE levels <200 mg/g (in the 
absence of diarrhea) has been proposed as an 
indicator of pancreatic in- sufficiency and a 
diagnostic marker for CF. FE values fluctu- ate 
through the fi 12 months of life. In a study76 of 61 
infants diagnosed with CF through NBS, 48 infants 
(79%) had initial FE <200 mg/g; 13 of these 48 
infants (27%) had a least 1 FE value >200 mg/g 
over the next several months before resolv- ing 
into levels <200 mg/g, and 4 of 48 infants (8%), on the 
other hand, displayed pancreatic-sufficient levels 
>200 mg/g by >9 months of age. In addition, 13 
infants (21%) had initial FE 
>200 mg/g; 10 of these (77%) had pancreatic 
sufficiency at the end of the first year of life. 
FE may be useful as an interim measure in those 
infants with pancreatic insuffi    who have “quantity 
not suffi    ” sweat test results, permitting appropriate 
treatment until repeat sweat testing is successful. This 
strategy has been used in Switzerland.77 However, 
despite the early enthusiasm for this biomarker,78,79 
FE is of limited value in diagnosing CF definitively, as 
many individuals with CF retain normal levels of 
FE.76,80 It also has been disappointing when used 
to try to determine which infants, categorized as 
CFSPID from a newborn screen, will eventually be 
diagnosed with CF.81 When FE levels were mea- sured 
over the first 24 months of life in a cohort of 36 
infants with CFSPID, all but one remained >200 
mg/g, and none of 
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the babies later diagnosed with CF displayed low 
FE levels, re- maining pancreatic sufficient (Tanja 
Gonska, personal com- munication, October 
2015). 
 
Trypsinogen 
Trypsinogen levels are already used to identify 
infants at high risk for CF and may be used to 
better advantage. Serum tryp- sinogen levels 
were serially examined over the first 36 months of 
life in 82 infants categorized as CFSPID and 80 
infants di- agnosed with CF.81 Overall, infants with 
CFSPID had signifi- cantly lower NBS IRT than did 
infants with CF. Furthermore, nine of the 82 (11%) 
infants with CFSPID were subsequently 
diagnosed with CF, and these patients had 
significantly higher serial serum trypsinogen 
levels than did those infants who re- mained in 
the group with CFSPID. Thus, serial trypsinogen 
levels may contribute useful information. 
 
NPD and ICM 
As in the 1996-1998 and 2007-2008 CF 
Foundation consen- sus development processes, 
the overwhelming importance of demonstrating 
CFTR dysfunction to confirm a CF diagnosis, 
combined with the limitations of sweat tests, 
creates great appeal for other CFTR functional 
assays. This is especially true for those assays 
providing added value from an in vivo strategy 
and a drug responsiveness component that 
increases sensitivity. 
Measurements of CFTR (and the epithelial 
sodium channel) activity in nasal epithelium 
readily distinguish the healthy young infant from 
one with CF. In fact, NPD, when attempted in 
babies with intermediate sweat chloride levels 
by very expe- rienced, skilled operators, can 
provide reliable results. In 1 study of 11 children 
(aged 3.5 ± 1.5 years) with nondiagnostic sweat 
chloride values, NPD testing was able to 
demonstrate normal CFTR function in 7 of the 
children; only 1 showed NPD in- dicative of 
pathology (the test could not be completed in 3 
chil- dren because of poor cooperation) 
(Michael Wilschanski, personal 
communication, October 2015). Another study 
of NPD conducted in 23 young children (aged 
3 months to 4 years) with high IRT values, 1 CF-
causing mutation identi- fi and intermediate 
sweat chloride levels demonstrated a con- 
nection between NPD results and clinical 
outcome.82 Although NPD results were not 
interpretable in 2 of the children, 13 of the 21 
remaining children (62%) had NPD scores in the 
CF range; 2 CFTR mutations were subsequently 
found in all 13 patients, and 9 of the 13 had 
developed chronic lung disease at follow-up. Of 
the 8 children (38%) with normal NPD scores, only 
2 children had 2 CFTR mutations (both of which 
are as- sociated with a wide spectrum of 
phenotypes), and none had developed a CF-like 
lung disease at follow-up. Repeated sweat test 
results were obtained in 5 of these 8 children; all 
had sweat chloride values <60 mmol/L. A CF 
diagnosis was ruled out in 6 of the 8 children. 
However, NPD is not possible or reliable in 
every situa- tion, and analysis of CFTR function in 
the intestine (ICM) may be considered, aided by 
the fact that CFTR is highly ex- pressed in 
intestinal epithelia, offering high specifi y and sen- 
sitivity for the test.83,84 Like NPD, ICM measurements 
must be 
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conducted in specific high quality reference 
centers with ex- perienced, very skilled 
personnel.85,86 ICM can be used to confirm a 
diagnosis of CF in the context of intermediate sweat 
chloride levels.87,88 Ion transport in the intestine is a 
very sen- sitive measure of CFTR function: only 10% 
of wild-type CFTR is necessary to prevent intestinal 
pathology in CF, and a very small gain in CFTR 
expression (from 1% to 5% of wild- type) results 
in large gains in chloride secretion (from 5% to 
25% of wild-type levels).83 Because of this sensitivity, 
ICM can be used to better characterize variants 
of unknown disease liability. 
Combining results from ICM and NPD, when 
available, can provide an even clearer picture of the 
spectrum of CFTR function, from CF-causing to 
healthy levels (Isabelle Sermet- Gaudelus, personal 
communication, October 2015). If the ICM is 
normal, other pathologies, such as 
immunodysregulation polyendocrinopathy 
enteropathy X-linked syndrome, should be 
considered. 
NPD and ICM have the potential to be useful as 
surrogate outcomes because they are in vivo/ex 
vivo measurements and may play a useful 
supplementary role for the diagnosis of CF (Table 
I, statement 15). However, they are not sufficiently 
vali- dated at present to recommend routine use 
and are not avail- able on a wide scale because of 
the expertise and experience required to obtain 
reliable measurements (Table I, statement 14). 
Nevertheless, these are increasingly attractive, 
advanced research methods that will help us better 
understand the nature of the spectrum of CF 
disease and CRMS/CFSPID. And, with more routine 
use in European CF centers, greater applica- tion 
will undoubtedly occur. 
Despite these advances, some infants still 
provide a diag- nostic challenge. Thus, long-term 
follow-up evaluations of children with various 
levels of CFTR function are needed to determine 
the best approach for diagnosis and management 
of children without the signs and symptoms of 
established, unequivocal CF. The best approach 
may involve sensitive functional tests such as 
NPD and ICM tests in combination with 
genotype-phenotype studies (such as correlation 
with the CFTR2 database6) and data collected 
from CF registries. 
 
Clinical/Respiratory Evaluations in Uncertain 
Cases 
Clinical evaluations for respiratory pathology are of 
little value 
in cases of uncertain CF during infancy. Signs and 
symptoms are unlikely and nonspecific, although 
chronic cough should raise suspicion. An infant 
pulmonary function test (PFT) that demonstrates 
gas trapping or reduced forced expiratory flows 
could be of value, but the measurement is not 
standardized, the capability of performing an infant 
PFT is not widely avail- able, and other obstructive 
lung problems (such as wheezing) can produce 
similar PFT results.89 Lung clearance index using the 
SF6 method for infants is sensitive, but again, not 
widely available (N2 washout is not currently 
developed for infants).90-92 Chest radiographs are 
worthwhile, but the changes are often subtle and 
nonspecifi Chest computed tomography scans per- 
formed in infants diagnosed with CF following NBS 
through the Australian Respiratory Early Surveillance 
Team for CF in- 
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tensive surveillance program revealed 29.3% with 
bronchiec- tasis by 3 months of age,93 although fi 
s differed in a United Kingdom cohort.94 This 
finding is in keeping with earlier ob- servations 
from autopsy-based studies.95 However, a study 
of chest computed tomography in asymptomatic 
infants with CF suggested that this imaging is 
usually not warranted because the changes 
during infancy are typically very mild.94 Thus, in 
uncertain cases, the radiation burden and risks of 
anesthesia are unlikely to be balanced by 
benefit. 
Induced sputum or bronchoalveolar lavage 
performed in children with CF aged 3 to 7 years 
may reveal evidence of bac- teria common in CF, 
including Pseudomonas aeruginosa, 
Stenotrophomonas maltophilia, and Staphylococcus aureus.96 
To understand the significance of culturing CF-
typical bacteria in this population, respiratory 
samples collected over the first 2 years of life in 
children with either CF (n = 23) or non-CF chronic 
suppurative lung disease (n = 124) were 
compared by retrospective analysis (Hannah 
Blau, personal communica- tion, October 2015). 
At the time of the first culture, there was no 
significant difference between the bacterial 
species cul- tured from children with CF 
compared with those cultured from children 
with other lung diseases. However, when all 
sputum culture results from the fi 2 years were 
analyzed, cul- tures from children with CF were 
significantly more likely to contain P aeruginosa, 
Enterobacter species, Escherichia coli, Kleb- siella oxytoca, 
and Serratia species than were control cultures. P 
aeruginosa-positive cultures were found in 32/124 
(about 26%) of the children with non-CF lung 
disease compared with 17/23 (74%) children with 
CF, although chronic P aeruginosa infection was 
rare in either case. The conclusion from this ret- 
rospective analysis is that cultures from induced 
sputum may provide a useful disease marker in 
the infant with suspected CF. 
 
 
Consensus Statements on Diagnosing 
CF in Screened Populations 
 
Taking into account the available evidence, the 
2015 CF Foun- dation Consensus Committee 
agreed upon the statements shown in Table I 
for diagnosing screened populations. Sweat 
tests, CFTR mutation analysis, and the ancillary 
tests de- scribed above may all prove valuable 
for establishing or con- fi ming a CF diagnosis in 
children with positive prenatal testing or neonatal 
screening. The European CF Society Standards of 
Care state that the majority of infants with a 
confirmed di- agnosis after NBS should be seen 
by the specialist CF team by 35 days of age and no 
later than day 58,62 whereas the recom- mended 
US standard of care specifies diagnosis by 2-4 
weeks without specifying care at a CF center.9 
Therefore, to ensure timeliness, follow-up 
evaluations needed to decide CF status should be 
completed within 2-4 weeks of age when infants are 
hopefully still in a preclinical stage. Even by 2 weeks, 
however, malnutrition may be present,97,98 and 
there is a risk of poten- tially fatal electrolyte 
depletion and hyponatremic dehydration99 
(Appendix, case study 3). Hence, it is important in 
some cir- cumstances to make a presumptive 
diagnosis of CF to enable 
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appropriate treatment and follow-up while 
pursuing diagnos- tic confirmation (Table I, 
statement 4). 
Once a diagnosis is established, genetic 
counseling should be offered to families of all 
infants with CF or CRMS/CFSPID.18,19,57,100 In other 
words, all families of CF NBS positive newborns 
should receive genetic counseling, whether the 
infant turns out to be a carrier or is truly affected. 
Rec- ommendations have been published on 
methods of genetic counseling.101,102 
 
Enrollment into the US CF Foundation 
Patient Registry 
 
The US CF Foundation Patient Registry was 
created in 1966 to collect data on health 
outcomes, clinical care and demo- graphic 
characteristics of people with CF who receive care 
at CF Foundation-accredited care centers.103 Clear, 
reliable data must be entered into the CFFPR 
and other registries to permit quality analysis of 
CF NBS programs and clinical outcomes of all 
those with CF. Entering diagnostic informa- tion 
under consistent guidelines is critically important 
for all patients diagnosed with the disease, 
including those diag- nosed immediately 
following a positive newborn screen, as well as 
those diagnosed at a later age, such as those with 
a false-negative newborn screen, or those who 
had a positive newborn screen and a negative 
initial sweat test. It is impor- tant to accurately 
record dates, test results, and treatment from 
the initial contact. Because CFFPR consent often is 
not obtained until the patient has been seen at 
the CF center for 1 or more visits, it is essential to 
ask families for consent as soon as possible to allow 
retrospective data (ie, before consent) to be 
entered in the registry, subject to institutional 
review board approval. Appropriate guidelines 
for data entry on consented patients diagnosed 
following prenatal screening or NBS are 
presented below. 
 
Guidelines for Date of Confirmation of CF 
Diagnosis following Prenatal Testing 
Prenatal testing showing 2 CF-causing CFTR 
mutations (in trans, as confirmed by parental 
testing) is generally adequate for a presumptive 
diagnosis of CF. In most cases, prenatal testing 
is done when both parents are known carriers 
either because of population screening with 
cascade testing or as a result of testing because of 
a positive family history. However, because of 
varying prenatal testing and reporting protocols, 
infants with prenatal diagnosis should have the 
date of diagnosis listed as the date of birth (ie, 
diagnosed at 1 day of 
age). In addition, infants with positive prenatal 
testing results should always have a sweat test 
performed for confirmation of the diagnosis. 
 
Guidelines for Date of Presumptive Diagnosis in 
CF NBS 
It is important to provide a date of presumptive 
diagnosis for the purpose of evaluating 
timeliness of diagnosis and treatment by CF 
centers in conjunction with NBS programs. 
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An infant can be presumed to have CF in any of 
the following clinical circumstances: (1) positive CF 
NBS test result reveals 2 CF-causing CFTR 
mutations; (2) CF NBS test is positive based on a 
specific state’s algorithm, and there are clinical 
features consistent with CF, such as growth failure 
or malabsorption; or (3) infant has meconium ileus, 
with or without a positive CF NBS test. 
In each of these cases, confirmation of 
diagnosis should proceed as quickly as possible, 
but treatment should not be delayed while 
awaiting diagnostic confirmation. 
 
Guidelines for Date of Confirmation of CF 
Diagnosis Subsequent to NBS 
A sweat test should be performed in all cases of 
presumptive 
diagnosis, as soon as possible. It may be delayed 
because of illness, prematurity, or, rarely, other 
circumstances (eg, geo- graphic or weather-
related) but should not otherwise be delayed. A 
CF diagnosis is considered confirmed only if: (1) 
sweat chloride is ≥60 mmol/L; (2) CF-causing 
CFTR muta- tions are identified and the sweat 
chloride value is ≥30 mmol/ L; (3) 2 variable or 
uncharacterized CFTR mutations are identified 
and physiological testing such as NPD or ICM 
reveal CFTR dysfunction, and the sweat chloride 
value is 
≥30 mmol/L; (4) 2 CF-causing CFTR mutations 
are identi- fied from a blood specimen obtained 
directly from the affected infant during follow-
up—a genotype report from the NBS program 
is not sufficient because of the risk of errors 
(parental testing may be required in some 
circum- stances to verify that 2 mutations are 
in trans,60 in cases where genotype and CFTR 
functional testing results are at variance [eg, 
normal sweat value and 2 CFTR mutations are 
present]); or (5) NPD or ICM values typical of 
CF are present (CF-typical values must be 
defined by an experi- enced center performing 
the test). 
 
Guidelines for Date of Confirmation of CF 
Diagnosis Because of “Diagnostic Drift” or 
Because of Genetic Reclassification 
A change to a CF diagnosis most often occurs 
when an infant 
initially categorized as CRMS/CFSPID develops 
clinical signs or symptoms of CF. In these cases, 
the CFFPR entry should note the date of clinical 
diagnosis of CF, as well as the date of the onset of 
clinical or laboratory fi       s that led to the change 
in diagnostic category (such as an increase in 
sweat chloride into the diagnostic range, or 
infection with P aeruginosa). 
Rarely, children may move from the 
CRMS/CFSPID cat- egory to a CF diagnosis 
because of a new recognition of the pathologic 
consequences of their CFTR alleles. In these cases, 
the CFFPR entry should be updated to the date for 
reclassi- fication of their genotype. 
The guidelines described above should enhance 
the quality of data in the CFFPR. Other CF 
registries may wish to con- sider these 
recommendations. It would be ideal to have inter- 
national harmony and consistency in the global CF 
registries. Perhaps the proper use of International 
Statistical Classifica- tion of Diseases and Related Health 
Problems, 10th Revision codes on an international 
scale, refl a clear 
application of 
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diagnostic categories created by consensus, would 
contribute to harmony. 
 
Educational Resources 
 
The diagnosis of CF has become increasingly 
complex, as CFTR mutations resulting in a wide 
spectrum of dysfunction have been increasingly 
identifi To address this challenge and help 
educate CF centers and care providers in CF 
diagnosis, efforts will be put in place to facilitate 
implementation. Additional educational 
resources are also available (Table II). 
 
Conclusions 
 
Prompt diagnosis of CF is vital for optimizing 
outcomes. The widespread use of CF NBS has 
enabled the diagnosis of CF in most affected 
infants before obvious clinical signs, but di- 
agnosis can be diffi  To take advantage of 
burgeoning knowl- edge of the impact of various 
CFTR mutations and recent studies on cohorts 
with unclear CF diagnoses, the CF Foun- dation 
convened a committee of experts from around the 
world to update consensus guidelines on 
diagnosis of CF with an em- phasis on screened 
populations. The committee concluded that all 
diagnoses should be established by 
demonstrating CFTR dysfunction—by sweat 
chloride test where possible, or poten- tially by 
other methods such as NPD or ICM where 
neces- sary. Even in babies with 2 CF-causing 
mutations detected by NBS, diagnosis must be 
confirmed by demonstrating CFTR dysfunction. 
Guidelines for making a presumptive diagnosis 
were also developed. Following the 
recommendations for screened populations 
should provide clarity to CF care pro- viders and 
families, and ensure treatment is provided when 
needed, while avoiding medicalization of healthy 
infants. ■ 
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Appendix  
Sweat Cl− 
 
Sweat Cl− 
 
Sweat Cl− 
Case Study 1 
A 1-week-old female infant presents to the 
pediatrician for a 
Mutation 1   Mutation 2   <30 mmol/L = 30-59 mmol/L ≥60 mmol/L 
CF-causing   CF-causing CF CF CF 
CF-causing  MVCC CRMS/CFSPID CRMS/CFSPID CF 
first visit following an uneventful pregnancy and normal 
vaginal delivery. She has been steadily improving 
in the time that she breastfeeds and is currently 
now at birth weight 
CF-causing   Unknown 
significance 
(not in 
CFTR2) 
CRMS/CFSPID CRMS/CFSPID CF 
after being several ounces down at her discharge on day 2. 
Parents are concerned that she sneezes and has 
some nasal stuffi The  physical  examination  is  
within  normal limits. 
She was born in a state that uses IRT/DNA for CF 
NBS and was positive for 2 mutations: c.350G>A 
mutation (legacy: R117H) and c.1521_1523delCTT 
(legacy: F508del). The polyT intron analysis 
revealed 7T/7T. 
What is the recommended next step by the 
pediatrician for the evaluation of this infant? 
 
 
A. Referral to a CF center for evaluation and sweat chloride testing 
B. Observe for 1 y and refer to CF center if clinical symptoms 
suggestive of CF develop 
C. Send for detailed genetic analysis of CF gene 
D. Send for sweat testing at accredited laboratory and observe for 1 y 
of life with referral to CF center if symptoms develop 
A—correct 
A sweat test is obtained at an accredited laboratory, and sweat chloride value is 
Not available Not available   CF unlikely CRMS/CFSPID CF 
 
 
 
Case Study 2 
A 1-week-old male infant presents for his first visit 
to the primary care physician. He was born at 34 
weeks’ gestation and was screen-positive because 
of high IRT and 1 CF- causing mutation, F508del, 
on his CF newborn screen test. During this visit, he 
is noted to be feeding well and is a few ounces over 
his birthweight of 4 pounds (1.8 kg). His history is 
negative for respiratory symptoms, and there is no 
family history of cystic fibrosis. 
His physician refers him to the local hospital for 
a sweat chloride test as per protocol. At 9 days 
of age, the test is completed, and results in 
quantity not sufficient for testing (QNS). 
What is the next step for this infant? 
33 mmol/L. The infant was seen at an accredited CF center where a negative    
history was obtained, and she had a normal physical examination. 
 
 
 
 
What is the most likely diagnosis of this infant 
at this time? 
 
 
A. CF 
B. CRMS/CFSPID 
C. Atypical CF 
D. CFTR-related disorder 
B—correct 
The diagnosis of CRMS or CFSPID is given after a positive newborn screen and: a 
sweat test value less than 30 mmol/L and 2 CFTR mutations, at least 1 of 
which has unclear phenotypic consequences; or an intermediate sweat 
chloride value (30-59 mmol/L) and 1 or no CF-causing mutations. In this infant, 
the R117H with 7T is the mutation that is unclear in its clinical significance but 
in a few patients has been associated with the development of symptoms 
consistent with CF. The term CRMS/CFSPID is reserved for those screen- 
positive infants without clinical features consistent with CF. Following 
consensus guidelines from 2008 would have resulted in considering this infant 
not to have CF, and no follow-up would be recommended. The new guidelines 
are specific that this infant should receive an evaluation and education at an 
accredited CF center. This is a significant shift in guidance. 
Children designated as CRMS/CFSPID should undergo at least 1 repeat sweat 
chloride test at a CF center with suitable expertise, such as an accredited CF 
center. This is often done when the infant is 6 months of age. Some centers 
repeat again at 2 years of age. 
These infants and children may benefit from continued clinical evaluation by CF 
providers at the accredited CF centers along with regular care from their 
primary care providers to monitor for signs and symptoms of CF. A minority of 
these infants may develop changes in their physiologic testing along with 
clinical symptoms that ultimately lead to a diagnosis of CF. 
 
 
 
 
Guide to initial diagnosis in cases where 2 
mutations have been identified through NBS or no 
genes identified in IRT/ IRT CF NBS algorithm: 
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A. Repeat testing when he is corrected 36 wk of age and is 2 kg 
in weight 
B. Repeat testing at an accredited laboratory 
C. Repeat testing when tolerating feedings and is well hydrated 
D. All of the above 
D—correct 
The sweat test was performed when his weight reached 2 kg and was 
normal with a sweat chloride value of 12 mmol/L. The infant is 
considered to be a carrier for CF. 
 
 
What should be done next for this infant? 
 
 
A. Discuss the testing results with the parents and refer for 
genetic counseling 
B. Repeat the sweat test at 6 mo of age 
C. Send for expanded genetic mutation analysis 
D. Refer all siblings for sweat testing to verify the negative result 
A—correct 
Newborns with a positive CF NBS test should be tested when at least 36 wk 
gestation and 2 kg body weight. Testing should be completed no later than 
10-28 d of age at an accredited laboratory in a healthy full term newborn 
with a positive CF NBS test. 
In this case, the carrier state was detected by CF NBS testing. The incidence of 
carrier testing has been found to be decreased in those states that use the 
sequence of IRT/IRT/DNA testing. Genetic counseling is recommended for the 
families of all infants that screen positive for CF including those with carrier 
status. 
It is important to recognize that CF NBS testing, except perhaps for those areas 
that use IRT/expanded DNA testing, is not designed to detect the carrier state. 
A negative NBS test in the majority of cases does not exclude that the infant is 
a carrier of CF. 
 
 
 
 
Case Study 3 
A female infant was born at 38 weeks’ gestation 
with a birth weight of 2.8 kg to African American 
parents. Prenatal screen- ing for CFTR carrier 
status revealed that the mother carried a 
common disease-causing CFTR mutation—
c.1652G>A 
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− 49.6 mEq/L (23-30). An 
 
(legacy: G551D). The father was tested via a 23-
mutation panel (American College of 
Obstetricians and Gynecologists) that detected 
common mutations and was found to have no 
mutations. 
The infant had a positive CF NBS test with an 
elevated IRT and was positive for 1 mutation—
G551D. She was followed by her primary care 
physician, and at 2 weeks of age, she was found to 
be breastfeeding well but the weight had 
decreased to 2.3 kg. A sweat test was ordered and 
had QNS for analysis. At 4 weeks of age, she was 
seen again and weighed 2.2 kg, and a repeat sweat 
test was again QNS. A third sweat test at 6 weeks of 
age was positive with results of 89 and 94 mmol/L. 
She was then seen at a CF center and was 
started on pancreatic enzyme replacement 
therapy, albuterol, and chest physiotherapy. 
Further testing was completed. Fecal pancre- atic 
elastase was low at <15 mg/g. She was found to 
have her mother’s mutation as well as a rare 
second disease-causing mutation that her father 
had not been tested for during prenatal testing. 
Slow weight gain was then established during a 
subsequent visit to the CF center and her 
primary care physician. 
At 3 months of age, the infant presented to an 
emergency department for poor feeding. She was 
noted to have a 3-day history of reduced oral 
intake and irritability without cough or rhinorrhea. 
Over the previous 24 hours, she had eaten very 
little by mouth and had only 2 wet diapers. On 
physical ex- amination, she was afebrile but 
lethargic and had dry tacky mucous membranes. 
Her weight was at the first percentile for 
age. Her chest was clear, and her abdomen 
was soft and nontender. 
The most likely etiology of the current fi s in 
this infant with CF is: 
 
 
A. Chronic malnutrition 
B. Acute pulmonary exacerbation of CF 
C. Distal intestinal obstruction syndrome 
D. Electrolyte  abnormalities 
D—correct 
This infant presents with acute changes in behavior and feeding suggestive of 
electrolyte abnormalities; she had not been prescribed supplemental salt, a 
recommendation of the CF Foundation clinical practice guidelines for infants 
with CF. A basic metabolic panel showed Na+ 119 mEq/L (134-146); K+ 
1.9 mEq/L (4.2-6.4); Cl− <60 mEq/L (98-108); HCO3 
electrocardiogram revealed first degree atrioventricular block and a prolonged 
QTc interval. She was hospitalized in the intensive care unit for 1 wk and was 
hospitalized for a total of 4 wk. 
This case illustrates risk factors for delayed diagnosis after a positive CF NBS. 
Because the infant was from a racial minority with a lower incidence of CF, and 
because her mother was a carrier of a CFTR gene mutation but her father was 
found to have a “negative” carrier test, her initial positive NBS test was thought 
to be reflective of a carrier status. Even though sweat testing was ordered 
within an appropriate time interval, the QNS values were thought to be due to 
inadequate weight gain, and she was not evaluated for the possibility that 
pancreatic insufficiency was the underlying cause of this poor postnatal weight 
gain. 
Her diagnosis was delayed until after the first month of life and, in addition, salt 
was not prescribed. She subsequently developed a severe, life-threatening 
electrolyte imbalance and notably this occurred during the winter in a cold 
climate. In infants with a positive newborn screen and poor growth, it is 
appropriate to make a “presumptive diagnosis” of CF, perform appropriate 
diagnostic studies, and treat empirically with pancreatic enzyme replacement 
therapy and salt until the diagnosis can be either confirmed or ruled out. 
